glycoside 3a

Glycoside 3a is an experimental small molecule N-acetylglucosamine (NAG) glycoside synthesized through the modification of a phenolic compound. It is being investigated as a novel therapeutic agent for Type 2 diabetes mellitus (T2DM) due to its potent inhibitory activity against α-glucosidase. Mechanistically, glycoside 3a binds to α-glucosidase, increasing the conformational flexibility of key residues and inducing structural looseness in the enzyme, which effectively inhibits its catalytic activity. In preclinical evaluations, its inhibitory effect was found to be comparable to the clinical standard acarbose, and it demonstrated cellular activity similar to metformin at high concentrations. As a marine-derived derivative, it represents a promising lead for further structural optimization in the development of carbohydrate-based antidiabetic medications.

Other names

N-acetylglucosamine glycoside 3aNAG glycoside 3a